Document Detail


CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
MedLine Citation:
PMID:  2575014     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CV 205-502 (CV) is a long-acting dopamine agonist with potent D2 and weak D1 activity, which has not as yet been tested in patients with Parkinson's disease. We performed a dosage ranging and placebo crossover study in six patients to evaluate the efficacy and tolerance of CV when used as an adjunct to Sinemet in patients with Parkinson's disease. All patients had striking improvement. This effect was lost with placebo substitution and regained with reintroduction of CV. Benefits were sustained throughout the 6 month study. Single daily dosing could sustain the response in all but one patient. Adverse effects were mild and transient and resolved with dosage manipulation or a divided dosage regimen. CV is a promising drug for use in Parkinson's disease and further studies are indicated to test its long-term safety and efficacy.
Authors:
C W Olanow; E G Werner; L L Gauger
Related Documents :
9270674 - Electromyography of the external anal sphincter in patients with parkinson's disease an...
18023964 - Silent aspiration in parkinson's disease patients with diurnal sialorrhea.
9448574 - Complementary pet studies of striatal neuronal function in the differential diagnosis b...
14616294 - Three-dimensional computerized analysis of diadochokinetic movements of parkinsonian pa...
18184944 - When epilepsy interferes with word comprehension: findings in landau-kleffner syndrome.
11885884 - Cardiovascular involvement in hiv/aids: report of 3 cases.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  12     ISSN:  0362-5664     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:  1989 Dec 
Date Detail:
Created Date:  1990-02-15     Completed Date:  1990-02-15     Revised Date:  2009-10-06    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  490-7     Citation Subset:  IM    
Affiliation:
Department of Neurology, University of South Florida, Tampa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aminoquinolines / administration & dosage,  therapeutic use*
Antiparkinson Agents* / administration & dosage,  adverse effects
Carbidopa / administration & dosage
Dopamine Agents / administration & dosage,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Drug Combinations / administration & dosage
Drug Evaluation
Drug Therapy, Combination
Female
Humans
Levodopa / administration & dosage
Male
Middle Aged
Parkinson Disease / drug therapy*
Chemical
Reg. No./Substance:
0/Aminoquinolines; 0/Antiparkinson Agents; 0/Dopamine Agents; 0/Drug Combinations; 0/Levodopa; 0/carbidopa, levodopa drug combination; 38821-49-7/Carbidopa; 87056-78-8/quinagolide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vasovagal syncope: management with atrioventricular sequential pacing and beta-blockade.
Next Document:  Comparison of tolerance to hydrophilic contact lenses made of Hema (37% H2O) and Hema-Degma (55%, 65...